Your browser is no longer supported. Please, upgrade your browser.
EVLO [NASD]
Evelo Biosciences, Inc.
Index- P/E- EPS (ttm)-2.22 Insider Own0.10% Shs Outstand53.38M Perf Week-13.07%
Market Cap398.90M Forward P/E- EPS next Y-2.08 Insider Trans0.00% Shs Float50.07M Perf Month-32.24%
Income-109.80M PEG- EPS next Q-0.54 Inst Own89.00% Short Float7.16% Perf Quarter-49.30%
Sales- P/S- EPS this Y11.10% Inst Trans-0.88% Short Ratio15.68 Perf Half Y-35.90%
Book/sh1.16 P/B6.25 EPS next Y5.50% ROA-89.00% Target Price- Perf Year60.40%
Cash/sh2.24 P/C3.24 EPS next 5Y- ROE-190.20% 52W Range3.82 - 19.93 Perf YTD-40.03%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-65.33% Beta1.43
Dividend %- Quick Ratio6.40 Sales past 5Y- Gross Margin- 52W Low80.89% ATR0.81
Employees90 Current Ratio6.40 Sales Q/Q- Oper. Margin- RSI (14)36.64 Volatility7.59% 10.72%
OptionableYes Debt/Eq0.00 EPS Q/Q6.50% Profit Margin- Rel Volume9.94 Prev Close7.25
ShortableYes LT Debt/Eq0.75 EarningsJul 29 BMO Payout- Avg Volume228.48K Price6.91
Recom2.10 SMA20-19.90% SMA50-27.36% SMA200-42.52% Volume1,982,418 Change-4.69%
Jun-23-21Initiated Cantor Fitzgerald Overweight $28
Apr-12-21Upgrade Jefferies Hold → Buy $11 → $18
Dec-23-20Initiated JMP Securities Mkt Outperform $27
May-21-20Downgrade Morgan Stanley Overweight → Equal-Weight $8
May-12-20Downgrade Jefferies Buy → Hold $18 → $6
Apr-30-19Initiated Jefferies Buy $18
Jan-29-19Initiated Chardan Capital Markets Neutral $10
Sep-27-21 12:11PM  
07:40AM  
02:00AM  
Sep-20-21 07:00AM  
04:58AM  
Sep-09-21 07:00AM  
Sep-08-21 08:30AM  
Sep-07-21 07:00AM  
Aug-06-21 08:46AM  
Jul-31-21 05:31AM  
Jul-29-21 07:00AM  
Jul-22-21 07:00AM  
Jul-14-21 04:01PM  
Jun-21-21 06:50PM  
Jun-16-21 04:01PM  
Jun-03-21 04:01PM  
Jun-01-21 07:00AM  
May-26-21 07:00AM  
May-25-21 06:00AM  
May-19-21 09:01AM  
May-13-21 07:00AM  
Apr-30-21 03:59PM  
Apr-29-21 03:01PM  
07:00AM  
06:30AM  
Apr-22-21 07:00AM  
Apr-20-21 04:01PM  
Apr-19-21 05:50AM  
Apr-15-21 07:00AM  
Apr-05-21 07:00AM  
Mar-30-21 09:30AM  
Mar-23-21 03:00AM  
Mar-09-21 05:00PM  
07:00AM  
05:30AM  
Mar-02-21 07:00AM  
Feb-16-21 07:00AM  
Jan-28-21 09:08PM  
04:01PM  
Jan-21-21 08:05AM  
Jan-20-21 07:00AM  
Jan-07-21 07:00AM  
Dec-23-20 10:07AM  
Dec-21-20 07:00AM  
Dec-14-20 11:21PM  
Dec-09-20 09:00AM  
07:00AM  
Dec-03-20 07:00AM  
Nov-27-20 10:47AM  
Nov-10-20 09:41AM  
Nov-09-20 08:00AM  
Oct-29-20 07:00AM  
06:30AM  
Oct-22-20 04:01PM  
Oct-15-20 07:00AM  
Oct-14-20 07:00AM  
Oct-13-20 07:00AM  
Oct-12-20 09:00AM  
Sep-14-20 07:06AM  
Sep-08-20 07:00AM  
Jul-30-20 07:00AM  
Jul-23-20 07:00AM  
Jul-07-20 08:00AM  
Jul-01-20 07:08AM  
Jun-24-20 07:56PM  
04:01PM  
Jun-22-20 02:00AM  
Jun-16-20 07:00AM  
May-29-20 12:00PM  
May-28-20 08:00AM  
07:00AM  
May-27-20 12:34PM  
11:30AM  
May-14-20 02:58PM  
May-11-20 07:00AM  
May-07-20 07:00AM  
May-04-20 09:00AM  
Apr-15-20 07:00AM  
Mar-05-20 07:00AM  
Mar-02-20 07:00AM  
Feb-25-20 12:09PM  
07:00AM  
Feb-13-20 07:00AM  
Feb-06-20 08:00AM  
Jan-10-20 07:00AM  
Dec-20-19 06:39PM  
Dec-19-19 08:00AM  
Dec-05-19 07:00AM  
Nov-13-19 08:01AM  
Nov-08-19 07:00AM  
Nov-05-19 07:01AM  
07:00AM  
Oct-29-19 08:00AM  
Sep-26-19 04:05PM  
Sep-20-19 07:00AM  
Sep-17-19 07:00AM  
Sep-03-19 08:00AM  
Aug-06-19 10:24PM  
07:01AM  
07:00AM  
Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in clinical development trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also engages in developing EDP1867, an inactivated investigational oral biologic for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Epstein David RDirectorSep 03Option Exercise0.009,850027,550Sep 03 04:55 PM
Flagship Ventures Fund IV Gene10% OwnerFeb 02Buy15.00130,0001,950,0004,125,461Feb 04 05:56 PM
Epstein David RDirectorDec 11Buy6.667,70051,26117,700Dec 14 05:15 PM
Liu Xiaoli JacquelinePrincipal Accounting OfficerDec 01Sale5.173,00015,5100Dec 02 04:44 PM